Recent Updates
Recently added Catalysts
ELUT Positive Sentiment Score: 70/100

Elutia to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Wednesday, November 13, 2024 1 min read
Key Takeaway: Elutia Inc. (Nasdaq: ELUT) has announced its participation in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum taking place in New York on November 21, 2024. Dr. Randy Mills, CEO, CFO Matt Ferguson, and CSO Dr. Michelle LeRoux Williams will meet with institutional investors during the conference. Elutia specializes in developing drug-eluting biomatrix products to improve medical device compatibility with patients. This engagement reflects the company's focus on advancing technologies to support an increasing patient population.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a prominent investor conference signals company growth potential.
  • Engagement with institutional investors may enhance funding opportunities.
  • Focus on drug-eluting biomatrix products aligns with increasing demand for implantable technologies.

Full Press Release Details

SILVER SPRING, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a leader in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, Matt Ferguson, Chief Financial Officer, and Dr. Michelle LeRoux Williams, Chief Scientific Officer, will participate in 1x1 investor meetings at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, November 21, 2024.
Institutional investors interested in meeting with management during the conference may reach out to their Canaccord representative.
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.
matt.steinberg@finnpartners.com

Frequently Asked Questions

What type of products does Elutia Inc. develop?

Elutia develops drug-eluting biomatrix products for medical devices.

Who is participating in the investor meetings?

Dr. Randy Mills, Matt Ferguson, and Dr. Michelle LeRoux Williams will attend.

When are the investor meetings taking place?

The meetings are scheduled for November 21, 2024.

How can investors arrange meetings with Elutia's management?

Investors should contact their Canaccord representative to schedule meetings.

What is Elutia's mission?

Elutia aims to humanize medicine and ensure patients thrive without compromise.

Tags: ELUT Viatris Investor Conferences Healthcare Elutia investor meeting Canaccord Genuity medtech biomatrix products
Last updated: Nov 13, 2024